AIPTO TechBio GmbH

AIPTO TechBio GmbH is a biotechnology company that operates as an official spinoff from the German Cancer Research Center (DKFZ). The company has developed a specialized technology platform called Individualized Patient Tumor Organoid (IPTO), which cultures patient tumor explants within brain organoids to create next-generation patient avatars. These avatars are designed to be diagnostically indistinguishable from the original tumors and accurately mirror their molecular tumor microenvironments. This avatar technology is complemented by a generative agentic AI system that utilizes single-cell data derived from the patient models to analyze drug responses, identify mechanisms of action, and predict potential treatment resistance at a single-cell level.

This platform aims to advance precision medicine and improve drug discovery pipelines for brain cancer. By offering the ability to predict clinical outcomes and recommend personalized counter-resistance treatment strategies, the company seeks to address the high failure rate of traditional clinical trials for brain tumors. The technology supports various stages of medical development, including target discovery, lead validation, and patient stratification. AIPTO collaborates with partners across academic, hospital, and industry sectors to translate its research into effective personalized treatment plans for brain cancer patients.